Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022)

Dianthus Therapeutics has reported Preferred Stock Liabilities over the past 2 years, most recently at $118.0 million for Q4 2022.

  • Quarterly results put Preferred Stock Liabilities at $118.0 million for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $118.0 million (changed N/A YoY), and the annual figure for FY2022 was $118.0 million, changed.
  • Preferred Stock Liabilities for Q4 2022 was $118.0 million at Dianthus Therapeutics, up from $92.4 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for DNTH hit a ceiling of $118.0 million in Q4 2022 and a floor of $118.0 million in Q4 2022.